IMM-101 + folinic acid + fluorouracil + oxaliplatin

This is a **combination therapy** comprised of IMM-101 (an immunomodulatory agent), folinic acid (leucovorin), fluorouracil (5-FU), and oxaliplatin. While FOLFOX (folinic acid, fluorouracil, and oxaliplatin) is a well-established chemotherapy regimen for colorectal and several other gastrointestinal cancers, IMM-101 is a heat-killed Mycobacterium obuense preparation that serves as a non-specific immune modulator, designed to stimulate the immune response against cancer. FOLFOX acts by targeting rapidly dividing cells, with each component having a unique mechanism: - **Fluorouracil** is a pyrimidine analog that inhibits thymidylate synthase, blocking DNA synthesis. - **Oxaliplatin** is a platinum-based chemotherapeutic that causes DNA crosslinking and apoptosis. - **Folinic acid** potentiates the cytotoxicity of fluorouracil by stabilizing the binding of 5-FU’s metabolite to thymidylate synthase. - **IMM-101** acts as an immunotherapy, stimulating both innate and adaptive immune responses against tumors. The combination aims to harness both immune system activation (via IMM-101) and direct cytotoxicity (via FOLFOX) for cancer treatment.

Other names

FOLFOX + IMM-101